Results of the Austrian National Lung Cancer Audit

Otto C Burghuber; Klaus Kirchbacher; Andrea Mohn-Staudner; Maximilian Hochmair; Marie-Kathrin Breyer; Michael Studnicka; Michael Rolf Mueller; Petra Feurstein; Andrea Schrott; Bernd Lamprecht; Josef Eckmayr; Friedrich Renner; Josef Bolitschek; Wolfgang Pohl; Peter Schenk; Peter Errhalt; Peter Cerkl; Bernhard Baumgartner; Meinhard Kneussl; Sylvia Hartl

doi:10.1177/1179554920950548

Results of the Austrian National Lung Cancer Audit

Otto C Burghuber, Klaus Kirchbacher, Andrea Mohn-Staudner, Maximilian Hochmair, Marie-Kathrin Breyer, Michael Studnicka, Michael Rolf Mueller, Petra Feurstein, Andrea Schrott, Bernd Lamprecht, Josef Eckmayr, Friedrich Renner, Josef Bolitschek, Wolfgang Pohl, Peter Schenk, Peter Errhalt, Peter Cerkl, Bernhard Baumgartner, Meinhard Kneussl, Sylvia Hartl

Division of Pneumology (University Hospital Krems)

Research output: Journal article (peer-reviewed) › Journal article

7 Citations (Scopus)

Abstract

OBJECTIVES: The Austrian Lung Cancer Audit (ALCA) is a pilot study to evaluate clinical and organizational factors related to lung cancer care across Austria.

MATERIALS AND METHODS: The ALCA is a prospective, observational, noninterventional cohort study conducted in 17 departments in Austria between September 2013 and March 2015. Participating departments were selected based on an annual case load of >50 patients with lung cancer.

RESULTS: The ALCA included 745 patients, representing 50.5% of all newly diagnosed cancer cases during that time period. In 75.8% of patients, diagnosis was based on histology, and in 24.2% on cytology; 83.1% had non-small-cell lung cancer, 16.9% small-cell lung cancer; and only 4.6% had to be classified as not otherwise specified cancers. The median time elapsed between first presentation at hospital and diagnosis was 8 days (interquartile range [IQR]: 4-15; range: 0-132); between diagnosis and start of treatment it was 15 days for chemotherapy (IQR: 9-27; range: 0-83), 21 days (IQR: 10-35; range: 0-69) for radiotherapy, and 24 days (IQR: 11-36; range: 0-138) for surgery, respectively. In 150 patients undergoing surgical treatment, only 3 (2.0%; n = 147, 3 missings) were seen with postoperative restaging indicating unjustified surgery. One-year follow-up data were available for 723 patients, indicating excellent 49.8% survival; however, a wide range of survival between departments (range: 37.8-66.7) was seen.

CONCLUSIONS: The ALCA conducted in high case load departments indicated management of lung cancer in accordance with international guidelines, and overall excellent 1-year survival.

Original language	English
Pages (from-to)	1179554920950548
Journal	Clinical Medicine Insights: Oncology
Volume	14
DOIs	https://doi.org/10.1177/1179554920950548
Publication status	Published - 2020

Access to Document

10.1177/1179554920950548

Cite this

Burghuber, O. C., Kirchbacher, K., Mohn-Staudner, A., Hochmair, M., Breyer, M.-K., Studnicka, M., Mueller, M. R., Feurstein, P., Schrott, A., Lamprecht, B., Eckmayr, J., Renner, F., Bolitschek, J., Pohl, W., Schenk, P., Errhalt, P., Cerkl, P., Baumgartner, B., Kneussl, M., & Hartl, S. (2020). Results of the Austrian National Lung Cancer Audit. Clinical Medicine Insights: Oncology, 14, 1179554920950548. https://doi.org/10.1177/1179554920950548

@article{6d8010a45f014bedb4c0ec8065005322,

title = "Results of the Austrian National Lung Cancer Audit",

abstract = "OBJECTIVES: The Austrian Lung Cancer Audit (ALCA) is a pilot study to evaluate clinical and organizational factors related to lung cancer care across Austria.MATERIALS AND METHODS: The ALCA is a prospective, observational, noninterventional cohort study conducted in 17 departments in Austria between September 2013 and March 2015. Participating departments were selected based on an annual case load of >50 patients with lung cancer.RESULTS: The ALCA included 745 patients, representing 50.5% of all newly diagnosed cancer cases during that time period. In 75.8% of patients, diagnosis was based on histology, and in 24.2% on cytology; 83.1% had non-small-cell lung cancer, 16.9% small-cell lung cancer; and only 4.6% had to be classified as not otherwise specified cancers. The median time elapsed between first presentation at hospital and diagnosis was 8 days (interquartile range [IQR]: 4-15; range: 0-132); between diagnosis and start of treatment it was 15 days for chemotherapy (IQR: 9-27; range: 0-83), 21 days (IQR: 10-35; range: 0-69) for radiotherapy, and 24 days (IQR: 11-36; range: 0-138) for surgery, respectively. In 150 patients undergoing surgical treatment, only 3 (2.0%; n = 147, 3 missings) were seen with postoperative restaging indicating unjustified surgery. One-year follow-up data were available for 723 patients, indicating excellent 49.8% survival; however, a wide range of survival between departments (range: 37.8-66.7) was seen.CONCLUSIONS: The ALCA conducted in high case load departments indicated management of lung cancer in accordance with international guidelines, and overall excellent 1-year survival.",

author = "Burghuber, {Otto C} and Klaus Kirchbacher and Andrea Mohn-Staudner and Maximilian Hochmair and Marie-Kathrin Breyer and Michael Studnicka and Mueller, {Michael Rolf} and Petra Feurstein and Andrea Schrott and Bernd Lamprecht and Josef Eckmayr and Friedrich Renner and Josef Bolitschek and Wolfgang Pohl and Peter Schenk and Peter Errhalt and Peter Cerkl and Bernhard Baumgartner and Meinhard Kneussl and Sylvia Hartl",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2020.",

year = "2020",

doi = "10.1177/1179554920950548",

language = "English",

volume = "14",

pages = "1179554920950548",

journal = "Clinical Medicine Insights: Oncology",

issn = "1179-5549",

publisher = "Libertas Academica Ltd.",

}

Burghuber, OC, Kirchbacher, K, Mohn-Staudner, A, Hochmair, M, Breyer, M-K, Studnicka, M, Mueller, MR, Feurstein, P, Schrott, A, Lamprecht, B, Eckmayr, J, Renner, F, Bolitschek, J, Pohl, W, Schenk, P, Errhalt, P, Cerkl, P, Baumgartner, B, Kneussl, M & Hartl, S 2020, 'Results of the Austrian National Lung Cancer Audit', Clinical Medicine Insights: Oncology, vol. 14, pp. 1179554920950548. https://doi.org/10.1177/1179554920950548

TY - JOUR

T1 - Results of the Austrian National Lung Cancer Audit

AU - Burghuber, Otto C

AU - Kirchbacher, Klaus

AU - Mohn-Staudner, Andrea

AU - Hochmair, Maximilian

AU - Breyer, Marie-Kathrin

AU - Studnicka, Michael

AU - Mueller, Michael Rolf

AU - Feurstein, Petra

AU - Schrott, Andrea

AU - Lamprecht, Bernd

AU - Eckmayr, Josef

AU - Renner, Friedrich

AU - Bolitschek, Josef

AU - Pohl, Wolfgang

AU - Schenk, Peter

AU - Errhalt, Peter

AU - Cerkl, Peter

AU - Baumgartner, Bernhard

AU - Kneussl, Meinhard

AU - Hartl, Sylvia

PY - 2020

Y1 - 2020

N2 - OBJECTIVES: The Austrian Lung Cancer Audit (ALCA) is a pilot study to evaluate clinical and organizational factors related to lung cancer care across Austria.MATERIALS AND METHODS: The ALCA is a prospective, observational, noninterventional cohort study conducted in 17 departments in Austria between September 2013 and March 2015. Participating departments were selected based on an annual case load of >50 patients with lung cancer.RESULTS: The ALCA included 745 patients, representing 50.5% of all newly diagnosed cancer cases during that time period. In 75.8% of patients, diagnosis was based on histology, and in 24.2% on cytology; 83.1% had non-small-cell lung cancer, 16.9% small-cell lung cancer; and only 4.6% had to be classified as not otherwise specified cancers. The median time elapsed between first presentation at hospital and diagnosis was 8 days (interquartile range [IQR]: 4-15; range: 0-132); between diagnosis and start of treatment it was 15 days for chemotherapy (IQR: 9-27; range: 0-83), 21 days (IQR: 10-35; range: 0-69) for radiotherapy, and 24 days (IQR: 11-36; range: 0-138) for surgery, respectively. In 150 patients undergoing surgical treatment, only 3 (2.0%; n = 147, 3 missings) were seen with postoperative restaging indicating unjustified surgery. One-year follow-up data were available for 723 patients, indicating excellent 49.8% survival; however, a wide range of survival between departments (range: 37.8-66.7) was seen.CONCLUSIONS: The ALCA conducted in high case load departments indicated management of lung cancer in accordance with international guidelines, and overall excellent 1-year survival.

AB - OBJECTIVES: The Austrian Lung Cancer Audit (ALCA) is a pilot study to evaluate clinical and organizational factors related to lung cancer care across Austria.MATERIALS AND METHODS: The ALCA is a prospective, observational, noninterventional cohort study conducted in 17 departments in Austria between September 2013 and March 2015. Participating departments were selected based on an annual case load of >50 patients with lung cancer.RESULTS: The ALCA included 745 patients, representing 50.5% of all newly diagnosed cancer cases during that time period. In 75.8% of patients, diagnosis was based on histology, and in 24.2% on cytology; 83.1% had non-small-cell lung cancer, 16.9% small-cell lung cancer; and only 4.6% had to be classified as not otherwise specified cancers. The median time elapsed between first presentation at hospital and diagnosis was 8 days (interquartile range [IQR]: 4-15; range: 0-132); between diagnosis and start of treatment it was 15 days for chemotherapy (IQR: 9-27; range: 0-83), 21 days (IQR: 10-35; range: 0-69) for radiotherapy, and 24 days (IQR: 11-36; range: 0-138) for surgery, respectively. In 150 patients undergoing surgical treatment, only 3 (2.0%; n = 147, 3 missings) were seen with postoperative restaging indicating unjustified surgery. One-year follow-up data were available for 723 patients, indicating excellent 49.8% survival; however, a wide range of survival between departments (range: 37.8-66.7) was seen.CONCLUSIONS: The ALCA conducted in high case load departments indicated management of lung cancer in accordance with international guidelines, and overall excellent 1-year survival.

UR - http://www.scopus.com/inward/record.url?scp=85090799352&partnerID=8YFLogxK

U2 - 10.1177/1179554920950548

DO - 10.1177/1179554920950548

M3 - Journal article

C2 - 32963472

SN - 1179-5549

VL - 14

SP - 1179554920950548

JO - Clinical Medicine Insights: Oncology

JF - Clinical Medicine Insights: Oncology

ER -

Results of the Austrian National Lung Cancer Audit

Abstract

Access to Document

Other files and links

Fingerprint

Cite this